Steven Novick

Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

Robert Z. Orlowski, Thomas E. Stinchcombe, Beverly S. Mitchell et al. · Journal of Clinical Oncology · 2002 · 763 citations

Medicine, Oncology, Pharmacology +17

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

Francis J. Giles, Philipp D. le Coutre, Javier Pinilla‐Ibarz et al. · Leukemia · 2012 · 248 citations

Medicine, Oncology, Pharmacology +8

Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia

Susan O’Brien, Charles Cunningham, A. Golenkov et al. · Journal of Clinical Oncology · 2005 · 191 citations

Pharmacy, Oncology, Pharmacology +17

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

Jun Guo, Richard D. Carvajal, Reinhard Dummer et al. · Annals of Oncology · 2017 · 166 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity

Guido Marcucci, Wendy Stock, Guowei Dai et al. · Journal of Clinical Oncology · 2005 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17